[
    [
        {
            "time": "2021-08-24",
            "original_text": "智通港股早知道 | (8月24日)原油强势反弹结束七连跌，海运运价回升至一年最高点",
            "features": {
                "keywords": [
                    "复星医药",
                    "新冠疫苗",
                    "mRNA技术",
                    "营收增长",
                    "创新药物"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智通港股早知道 | (8月24日)原油强势反弹结束七连跌，海运运价回升至一年最高点",
                "Correlation": 2,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 1,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-24",
            "original_text": "复星医药吴以芳：向创新药物迈进 不断提高创新品种收入比重",
            "features": {
                "keywords": [
                    "创新药物",
                    "收入比重",
                    "战略目标"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药吴以芳：向创新药物迈进 不断提高创新品种收入比重",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-24",
            "original_text": "复星国际：上半年净利润逾40亿元，快乐板块业务仍然亏损",
            "features": {
                "keywords": [
                    "净利润",
                    "亏损",
                    "快乐板块"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "多元化业务"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星国际：上半年净利润逾40亿元，快乐板块业务仍然亏损",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-24",
            "original_text": "中银证券维持复星医药增持评级：新品种进入收获期，金融资产价值提升",
            "features": {
                "keywords": [
                    "新品种",
                    "收获期",
                    "金融资产",
                    "价值提升"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中银证券维持复星医药增持评级：新品种进入收获期，金融资产价值提升",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-24",
            "original_text": "复星医药实现营业收入169.52亿元，同比增长20.85%",
            "features": {
                "keywords": [
                    "营业收入",
                    "同比增长",
                    "业绩增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药实现营业收入169.52亿元，同比增长20.85%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-08-24",
            "original_text": "全球首款mRNA新冠疫苗获批！将实现国内本地化生产",
            "features": {
                "keywords": [
                    "mRNA疫苗",
                    "FDA批准",
                    "本地化生产"
                ],
                "sentiment_score": 0.95,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "全球首款mRNA新冠疫苗获批！将实现国内本地化生产",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-24",
            "original_text": "复星医药出售公司资产，多家药企开启“瘦身模式”",
            "features": {
                "keywords": [
                    "资产出售",
                    "瘦身模式",
                    "战略调整"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药出售公司资产，多家药企开启“瘦身模式”",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-24",
            "original_text": "复星医药半年净利润25亿同比增45%，核心创新药单品收入增2倍",
            "features": {
                "keywords": [
                    "净利润",
                    "同比增长",
                    "创新药"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药半年净利润25亿同比增45%，核心创新药单品收入增2倍",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        }
    ]
]